Press coverage about G1 THERAPEUTICS (NASDAQ:GTHX) has trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. G1 THERAPEUTICS earned a daily sentiment score of 0.05 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 47.4600996879746 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

A number of equities research analysts recently issued reports on GTHX shares. Wedbush started coverage on G1 THERAPEUTICS in a research note on Monday, June 12th. They set an “outperform” rating and a $31.00 price target for the company. J P Morgan Chase & Co started coverage on G1 THERAPEUTICS in a research note on Monday, June 12th. They set an “overweight” rating and a $23.00 price target for the company. Needham & Company LLC started coverage on G1 THERAPEUTICS in a research note on Monday, June 12th. They set a “buy” rating and a $34.00 price target for the company. Finally, Cowen and Company reissued a “buy” rating on shares of G1 THERAPEUTICS in a research note on Wednesday, August 9th.

Shares of G1 THERAPEUTICS (NASDAQ GTHX) opened at 18.84 on Friday. G1 THERAPEUTICS has a 52 week low of $12.04 and a 52 week high of $20.60. The company’s 50 day moving average price is $15.16 and its 200-day moving average price is $16.29. The company’s market capitalization is $532.89 million.

G1 THERAPEUTICS (NASDAQ:GTHX) last posted its quarterly earnings results on Wednesday, August 9th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by $0.48. Analysts anticipate that G1 THERAPEUTICS will post ($2.92) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact G1 THERAPEUTICS (GTHX) Stock Price” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/01/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-g1-therapeutics-gthx-stock-price.html.

About G1 THERAPEUTICS

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Receive News & Stock Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related stocks with our FREE daily email newsletter.